NPCE241220P10000
- 0.00
- 0.000.00%
NeuroPace Newsroom
NeuroPace to Host Investor Day on January 28th in New York City
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
NeuroPace Completes Enrollment In Feasibility Study Of RNS System For Lennox-Gastaut Syndrome; Received A $9.3M National Institutes Of Health Grant Through The Brain Research Through Advancing Innovative Neurotechnologies Initiative To Evaluate Its...
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
Express News | Neuropace Completes Enrollment in Feasibility Study of Rns System for Lennox-Gastaut Syndrome
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $13
Strong Buy Recommendation for NeuroPace Amid Promising RNS System Results and Anticipated Market Advancements
What Makes NeuroPace (NPCE) a New Buy Stock
NeuroPace, Inc.'s (NASDAQ:NPCE) Shares Leap 42% Yet They're Still Not Telling The Full Story
NeuroPace Third Quarter 2024 Earnings: Beats Expectations
Neuropace Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Sales Guidance. Wells Fargo Maintained an Overweight Rating on the Stock.
NeuroPace Is Maintained at Overweight by Wells Fargo
NeuroPace Analyst Ratings
Morgan Stanley Maintains NeuroPace(NPCE.US) With Hold Rating, Maintains Target Price $8
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $13
Express News | Neuropace Inc : Wells Fargo Cuts Target Price to $13 From $15
NeuroPace's Strong Financial Performance and Strategic Advancements Justify Buy Rating
NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript Summary
NeuroPace | 10-Q: Q3 2024 Earnings Report